Vaxxinity EBITDA 2020-2023 | VAXX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Vaxxinity ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Vaxxinity ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Bristol Myers Squibb (BMY)	$115.2B
Gilead Sciences (GILD)	$114.5B
Vertex Pharmaceuticals (VRTX)	$104.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$78.6B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.1B
BioNTech SE (BNTX)	$27.6B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$20.8B
BeiGene (ONC)	$18B
Moderna (MRNA)	$16.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13.4B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.5B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.4B
Exact Sciences (EXAS)	$10.5B
Vaxcyte (PCVX)	$10.4B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8B